Submitted by Anonymous (not verified) on 6 June 2024 - 14:45
Opinion/decision on a Paediatric investigation plan (PIP): Evenity, Romosozumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0171/2023
Source: